Theriva Biologics (TOVX) has announced encouraging top-line results from its VIRAGE trial, sending its stock up over 40% to $1.92 in premarket trading Wednesday.
VIRAGE is a phase IIb trial testing the company's lead drug candidate, VCN-01, in combination with standard of care (SoC) chemotherapy (gemcitabine and nab-paclitaxel), as a first-line treatment for patients with metastatic pancreatic cancer - a group for whom this chemotherapy is the recommended first-line treatment option.
For comments and feedback contact: editorial@rttnews.com
April 10, 2026 16:21 ET Inflation data from the U.S. was the main data event this week as the conflict in the Middle East continue. The minutes of the latest Fed policy session and the survey data on the services sector also made headlines. In Europe, manufacturing orders data from Germany was in focus. Price data from China drew attention in Asia.